- Home
- CHRW vs EXAS Comparison
CHRW vs EXAS Comparison
Compare CHRW & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRW
- EXAS
- Stock Information
- Founded
- CHRW 1905
- EXAS 1995
- Country
- CHRW United States
- EXAS United States
- Employees
- CHRW N/A
- EXAS N/A
- Industry
- CHRW Oil Refining/Marketing
- EXAS Medical Specialities
- Sector
- CHRW Consumer Discretionary
- EXAS Health Care
- Exchange
- CHRW Nasdaq
- EXAS Nasdaq
- Market Cap
- CHRW 10.7B
- EXAS 10.7B
- IPO Year
- CHRW 1997
- EXAS N/A
- Fundamental
- Price
- CHRW $99.76
- EXAS $51.91
- Analyst Decision
- CHRW Buy
- EXAS Strong Buy
- Analyst Count
- CHRW 20
- EXAS 20
- Target Price
- CHRW $114.26
- EXAS $70.26
- AVG Volume (30 Days)
- CHRW 1.0M
- EXAS 2.8M
- Earning Date
- CHRW 07-30-2025
- EXAS 07-30-2025
- Dividend Yield
- CHRW 2.49%
- EXAS N/A
- EPS Growth
- CHRW 64.94
- EXAS N/A
- EPS
- CHRW 4.19
- EXAS N/A
- Revenue
- CHRW $17,359,385,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- CHRW N/A
- EXAS $14.58
- Revenue Next Year
- CHRW $4.76
- EXAS $12.75
- P/E Ratio
- CHRW $23.80
- EXAS N/A
- Revenue Growth
- CHRW N/A
- EXAS 11.57
- 52 Week Low
- CHRW $84.68
- EXAS $39.97
- 52 Week High
- CHRW $114.82
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- CHRW 59.70
- EXAS 44.34
- Support Level
- CHRW $96.34
- EXAS $52.00
- Resistance Level
- CHRW $102.58
- EXAS $55.90
- Average True Range (ATR)
- CHRW 2.06
- EXAS 2.31
- MACD
- CHRW 0.51
- EXAS -0.04
- Stochastic Oscillator
- CHRW 69.57
- EXAS 24.90
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.